NextBioMedical Co

NextBioMedical Co Rule of 40

The Rule of 40 of NextBioMedical Co (389650.KQ) as of Oct 20, 2026 is 68.30 %. In the previous year, Rule of 40 was 111.34 % — a change of -38.66% (lower).

Rule of 40

68.30 %

YoY

-38.66%

Last updated:

Rule of 40 of NextBioMedical Co is 2025 68.30 % . Rule of 40 of NextBioMedical Co was 2024 111.34 % . It decreases by -38.66% lower compared to the previous year.

The NextBioMedical Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2022
-150.67 KRW
Jan 1, 2023
-82.06 KRW
Jan 1, 2024
111.34 KRW
Jan 1, 2025
68.30 KRW
The NextBioMedical Co Rule of 40 history
YEARRule of 40YoY
68.30 %-38.66%
111.34 %-235.68%
-82.06 %-45.54%
-150.67 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd is a South Korean company operating in the Health Care sector, specifically within the Health Care Equipment & Supplies industry. Headquartered in Incheon, the company focuses on the manufacturing and sales of medical equipment. Its product portfolio includes endoscopic hemostatic agents and vascular embolic microspheres. The company also engages in research and development activities related to medical equipment. NextBioMedical Co Ltd completed its initial public offering (IPO) on August 20, 2024. The company's website is https://www.nextbiomedical.co.kr/. It operates as a manufacturer and seller of specialized medical devices, with no additional details provided regarding its founding year, key personnel, acquisitions, or financial figures. The company's operations are based in Incheon, South Korea, and it is listed under the ticker symbol 389650.KQ with ISIN KR7389650003. The company's primary business activities involve the production and distribution of medical equipment, emphasizing its role in the healthcare supply chain. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

Rule of 40 of NextBioMedical Co is 68.30 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Quality — NextBioMedical Co

AAQSPiotroski F-ScoreAltman Z-ScoreGraham NumberRule of 40

All Key Metrics — NextBioMedical Co